Aidence is a technology company.
Aidence has raised $14.0M across 2 funding rounds.
Aidence has raised $14.0M in total across 2 funding rounds.
Aidence has raised $14.0M in total across 2 funding rounds.
Aidence's investors include Northzone.
Aidence was an AI-powered radiology company that developed clinical applications for lung cancer management, primarily through its CE-certified Veye Lung Nodules solution, which automates the detection, quantification, and reporting of lung nodules in chest CT scans.[1][2][3][5] It served radiologists, pulmonologists, healthcare providers in lung cancer screening programs, and clinical research organizations by addressing radiologists' workloads, inconsistencies in diagnostics, and time constraints through seamless integration into PACS workflows, standardized reporting, and longitudinal analysis.[1][2][5] The company demonstrated strong growth momentum with deployments in over 80 European sites, NHS partnerships in the UK, collaborations with Google Health and AstraZeneca, and acquisition by RadNet in 2022, after which it was integrated into DeepHealth as DeepHealth Lung.[2][3][4][7]
Aidence was founded in November 2015 in Amsterdam by a team including co-founder and CEO Mark-Jan Harte, emerging from realizations about turning AI models into full medical devices beyond just algorithms.[2][3][6] The founders, initially handling multiple roles, recruited machine learning experts and clinicians in early 2016, growing from a basement team of seven to over 60 employees by focusing on pulmonary nodule management for routine practice and lung cancer screening.[6][7] Pivotal early traction included winning a 2017 Kaggle challenge for lung cancer prediction, securing a CE mark for Veye Lung Nodules, and building endorsements through research and conferences, leading to deployments and grants like €714k for expansion with Dutch cancer institutes.[3][4][6][7]
Aidence rode the wave of AI in medical imaging, particularly deep learning for radiology amid rising workloads and lung cancer screening demands, capitalizing on post-2018 Google Health research and EU MDR regulations to deliver deployable tools.[2][4][7] Timing aligned with national screening rollouts (e.g., UK's NHS program) and pharma needs for efficient trials, amplified by COVID-era AI pushes and grants.[3][7] Market forces like radiologist shortages and imaging volume growth favored its solutions, influencing the ecosystem by proving AI's real-world viability—accelerating adoption via partnerships with Google, AstraZeneca, and RadNet, and setting standards for regulated AI from research to clinical scale.[4][7]
As part of DeepHealth (RadNet subsidiary), Aidence's technology now scales across U.S. diagnostic imaging, with DeepHealth Lung pushing AI for nodule management globally where cleared.[2] Upcoming trends like expanded lung screening mandates, multimodal AI integration, and pharma trials will drive growth, evolving its influence from European pioneer to key player in AI-health informatics. This positions it to further reduce unnecessary procedures and boost early detection, building on its track record of turning AI research into life-saving, workflow-essential tools.[2][4]
Aidence has raised $14.0M across 2 funding rounds. Most recently, it raised $11.0M Series A in February 2019.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Feb 1, 2019 | $11.0M Series A | Northzone | |
| May 1, 2017 | $3.0M Seed | Northzone |